<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276809</url>
  </required_header>
  <id_info>
    <org_study_id>CLL3C</org_study_id>
    <secondary_id>EU-20556</secondary_id>
    <secondary_id>MEDAC-GCLLSG-CLL3C</secondary_id>
    <nct_id>NCT00276809</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German CLL Study Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving combination chemotherapy before a peripheral blood stem cell transplant&#xD;
      stops the growth of cancer cells by stopping them from dividing or killing them. Giving&#xD;
      colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells&#xD;
      move from the bone marrow to the blood so they can be collected and stored. A monoclonal&#xD;
      antibody, such as alemtuzumab, is given to kill any remaining cancer cells. Chemotherapy and&#xD;
      radiation therapy (total-body irradiation) are given to prepare the bone marrow for the stem&#xD;
      cell transplant. The stem cells are then returned to the patient to replace the blood-forming&#xD;
      cells that were destroyed by the chemotherapy and radiation therapy. Giving combination&#xD;
      chemotherapy, total-body irradiation, and alemtuzumab together with autologous peripheral&#xD;
      stem cell transplant may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with total-body irradiation and alemtuzumab works in treating patients undergoing an&#xD;
      autologous stem cell transplant for stage I, stage II, stage III, or stage IV chronic&#xD;
      lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and feasibility of cytoreductive fludarabine and cyclophosphamide&#xD;
           followed by high-dose myeloablative therapy comprising total-body irradiation,&#xD;
           cyclophosphamide, and alemtuzumab in patients undergoing autologous filgrastim&#xD;
           (G-CSF)-mobilized peripheral blood stem cell transplantation for stage I-IV chronic&#xD;
           lymphocytic leukemia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the clinical and molecular remission rate and duration in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open label, nonrandomized study. Patients are assigned to 1&#xD;
      of 2 cohorts according to time of enrollment.&#xD;
&#xD;
        -  Cytoreductive induction therapy: All patients receive fludarabine IV and&#xD;
           cyclophosphamide IV on days 1-3. Treatment repeats every 28 days for 2-4 courses in the&#xD;
           absence of disease progression or unacceptable toxicity. Patients achieving complete&#xD;
           response (CR) or partial response (PR) proceed to stem cell mobilization. Patients with&#xD;
           stage III or IV disease at this point are removed from study.&#xD;
&#xD;
        -  Stem cell mobilization: All patients receive Dexa-BEAM comprising oral dexamethasone&#xD;
           once daily on days 1-10; carmustine IV and melphalan IV on day 2; and cytarabine IV&#xD;
           twice daily and etoposide IV once daily on days 4-7. Patients also receive filgrastim&#xD;
           (G-CSF) subcutaneously beginning on day 8 and continuing until leukapheresis is&#xD;
           completed. Patients undergo peripheral blood stem cell (PBSC) harvest between days 20&#xD;
           and 28. Patients without an adequate number of collected PBSCs may receive a second&#xD;
           course of Dexa-BEAM. Patients achieving CR or very good PR proceed to high-dose&#xD;
           myeloablative therapy and PBSC transplantation (PBSCT) with or without consolidation&#xD;
           therapy.&#xD;
&#xD;
        -  Consolidation therapy: Beginning between 1-2 months after completion of Dexa-BEAM,&#xD;
           patients in cohort 2 receive alemtuzumab IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15,&#xD;
           17, 19, 22, 24, and 26 and then proceed to high-dose myeloablative therapy and PBSCT&#xD;
           within 1 month after completion of consolidation therapy. Patients in cohort 1 do not&#xD;
           receive consolidation therapy and proceed directly to high-dose therapy within 3 months&#xD;
           after completion of stem cell mobilization.&#xD;
&#xD;
        -  High-dose myeloablative therapy and PBSCT: Patients undergo total-body irradiation on&#xD;
           days -7 to -5. Patients then receive cyclophosphamide IV on days -4 and -3 and&#xD;
           alemtuzumab IV over 2 hours on days -10, -9, -8, -6, and -4. Patients undergo PBSCT on&#xD;
           day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and feasibility of CAMPATH-1H included into the myeloablative regimen (cyclophosphamide and TBI) of the CLL3 protocol monitoring of treatment related mortality and morbidity (CTC scale) continuous</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate and duration of molecular responses MRD levels continuous</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and duration of clinical remissions NCIE sponsored remission criteria for CLL continuous</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time from treatment to death continuous</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Chronic lymphocytic leukemia (CLL), meeting 1 of the following stage criteria:&#xD;
&#xD;
               -  Stage I-IV disease&#xD;
&#xD;
               -  Binet stage B or C disease&#xD;
&#xD;
               -  Binet stage A disease at high risk for rapid disease progression, as defined by&#xD;
                  both of the following criteria:&#xD;
&#xD;
                    -  Nonnodular marrow infiltration and/or lymphocyte doubling time &lt; 12 months&#xD;
&#xD;
                    -  Thymidine kinase &gt; 7.0 U/L and/or ß-2-microglobulin &gt; 3.5 mg/L&#xD;
&#xD;
          -  Polymerase chain reaction-amplifiable clonal CDR III rearrangement of the&#xD;
             immunoglobulin variable heavy chain gene&#xD;
&#xD;
          -  No Richter's syndrome or B-prolymphocytic leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  No concurrent disease resulting in major organ dysfunction&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent malignancy&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac failure&#xD;
&#xD;
          -  No cardiomyopathy&#xD;
&#xD;
          -  No history of myocardial infarction&#xD;
&#xD;
          -  No symptomatic coronary heart disease&#xD;
&#xD;
          -  No severe cardiac arrhythmia&#xD;
&#xD;
          -  No severe or uncontrolled hypertension&#xD;
&#xD;
          -  No chronic pulmonary disease&#xD;
&#xD;
          -  No pulmonary function test impairment&#xD;
&#xD;
          -  No severe or uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Bilirubin or transaminases ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine ≤ 1.4 mg/dL&#xD;
&#xD;
          -  No cerebral dysfunction&#xD;
&#xD;
          -  No severe psychiatric impairment&#xD;
&#xD;
          -  No drug addiction or alcoholism&#xD;
&#xD;
          -  Negative HIV&#xD;
&#xD;
          -  Negative Hepatitis B or C&#xD;
&#xD;
          -  No allergy to any of the protocol drugs&#xD;
&#xD;
          -  No history of anaphylactic reaction to monoclonal antibodies&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen OR chemotherapy that lasted &gt; 6 months&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No prior treatment with alemtuzumab&#xD;
&#xD;
          -  No prior long-term (&gt; 1 month) systemic corticosteroids&#xD;
&#xD;
          -  No prior therapy with dexamethasone, carmustine, etoposide, cytarabine, and melphalan&#xD;
             (Dexa-BEAM)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Stilgenbauer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dcllsg.de</url>
    <description>German CLL Study Group</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <keyword>stage 0 chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

